For decades, Parkinson’s disease treatment has focused mainly on replacing dopamine or easing movement problems.
While these medicines improve daily life, they cannot prevent the gradual loss of brain cells that causes the disease to worsen.
Researchers have therefore been searching for treatments that attack the disease at its source instead of only controlling symptoms.
A team from University Hospitals, Case Western Reserve University, and the Louis Stokes Cleveland VA Medical Center has now reported an encouraging breakthrough.
Their study, published in Redox Biology, suggests that blocking a single immune-related enzyme may protect brain cells and slow the damage caused by Parkinson’s disease.
Parkinson’s develops when dopamine-producing nerve cells gradually die. Scientists believe this damage results from several factors working together, including inflammation, oxidative stress, and the buildup of an abnormal protein called alpha-synuclein. Because the disease is so complex, finding effective treatments has been extremely difficult.
The researchers focused on an enzyme known as 15-PGDH. Previous studies from the same team showed that blocking this enzyme protected the brain in Alzheimer’s disease and traumatic brain injury. They wanted to know whether the same idea might work in Parkinson’s disease.
After studying human brain tissue and three different mouse models, the scientists found that 15-PGDH levels were consistently much higher than normal.
They then blocked the enzyme using both genetic techniques and experimental medicines. Brain inflammation fell, harmful oxygen molecules decreased, nerve cells survived in greater numbers, and the mice showed better movement and coordination.
The scientists also identified several inflammatory molecules that became much less active after the enzyme was blocked. These findings help explain why the treatment protects brain cells and provide important clues for future drug development.
An important advantage of this research is that drug development may move more quickly than usual. Experimental 15-PGDH inhibitors already exist, and one medicine called MF-300 has completed an early safety trial for another disease.
If future studies continue to produce positive results, researchers may be able to adapt these medicines for Parkinson’s disease rather than starting from the beginning.
Perhaps the most interesting result was that the treatment worked without lowering abnormal alpha-synuclein deposits.
This suggests that protecting brain cells from inflammation and oxidative damage may be just as important as removing the protein itself. It also gives researchers another possible treatment strategy beyond directly targeting alpha-synuclein.
The investigators will now study why 15-PGDH becomes overactive and how it interacts with other biological pathways in the brain. Answering these questions may reveal additional treatment targets and improve our understanding of several neurodegenerative diseases.
This research provides strong evidence from laboratory studies and multiple mouse models that blocking the 15-PGDH enzyme may protect brain cells in Parkinson’s disease. It is especially encouraging because a similar inhibitor has already completed an early Phase I safety trial for another condition, which could speed future development.
However, these findings have not yet been proven in people with Parkinson’s disease. Human clinical trials will be needed to confirm whether this approach is safe and can truly slow disease progression.
Even so, the study opens an exciting new direction by focusing on reducing brain inflammation and damage rather than directly targeting the abnormal proteins linked to Parkinson’s disease.
If you care about Parkinson’s disease, please read studies that Vitamin B may slow down cognitive decline, and Mediterranean diet could help lower risk of Parkinson’s.
For more information about brain health, please see recent studies that blueberry supplements may prevent cognitive decline, and results showing Plant-based diets could protect cognitive health from air pollution.
